Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team
May 07 2009 - 3:23PM
PR Newswire (US)
WAYNE, Pa., May 7 /PRNewswire-FirstCall/ -- Encorium Group, Inc.
(NASDAQ: ENCO), a full-service multinational contract research
organization (CRO) that provides design, development, and
management capabilities for clinical trials and patient registries
to many of the world's leading pharmaceutical companies, today
announced that Professor Hanna Nohynek, M.D., Ph.D. has been
appointed Head Consultant of Encorium's clinical vaccine research
team. Dr. Nohynek has an impressive track record in global clinical
vaccine development. She is currently a Member of the Global
Advisory Committee on Vaccine Safety of the World Health
Organization. She has recently served as an EU Commission appointed
member of the Health Security Working Group on platform for
development of counter bioterrorism medicinal products. She has
also recently been the Scientific Coordinator and/or
co-investigator in seven Phase II trials on a number of vaccines
(Haemophilus influenzae type b, meningococcal conjugate, and
pneumococcal conjugate among infants, and pneumococcal
polysaccharide among pregnant mothers and infants), as well as a
large Phase III pneumococcal conjugate vaccine trial conducted in
the Philippines with approximately 12,000 patients. Dr. David
Ginsberg, Encorium Group's Chief Executive Officer, stated, "We are
extremely pleased that Dr. Nohynek has agreed to join Encorium as
Head Consultant of our clinical vaccine research team. She brings a
truly global experience to our team and we look forward to working
with her." Dr. Kai E. Lindevall, Executive Chairman of Encorium
Group, added, "Dr. Nohynek is one of the leading experts in the
field of clinical vaccine development. She will substantially
strengthen our vaccine franchise and contribute to our ability to
conduct global vaccine trials. Her experience conducting vaccine
clinical trials in Asia-Pacific, in particular, should prove very
valuable for our clients." About Encorium Group, Inc. Encorium
Group, Inc. is a global clinical research organization specializing
in the design and management of complex clinical trials and Patient
Registries for the pharmaceutical, biotechnology and medical device
industries. The Company's mission is to provide its clients with
high quality, full-service support for their biopharmaceutical and
medical device development programs. Encorium offers therapeutic
expertise, experienced team management and advanced technologies.
The Company has drug and biologics development as well as clinical
trial experience across a wide variety of therapeutic areas such as
infectious diseases, cardiovascular, vaccines, oncology, diabetes
endocrinology/metabolism, gene therapy, immunology, neurology,
gastroenterology, dermatology, hepatology, women's health and
respiratory medicine. Encorium believes that its expertise in the
design of complex clinical trials, its therapeutic experience and
commitment to excellence, and its application of innovative
technologies, offer its clients a means to more quickly and cost
effectively move products through the clinical development process.
Encorium is headquartered in Wayne, Pennsylvania with its European
base of operations in Espoo, Finland. The Company has a geographic
footprint that includes over one billion people in North America,
Western/Central/Eastern Europe, Scandinavia, and the Baltics. This
press release contains forward-looking statements identified by
words such as "estimate," "project," "expect," "intend," "believe,"
"anticipate" and similar expressions regarding future expectations.
Those statements involve risks and uncertainties, and actual
results could differ materially from those discussed. Risks and
uncertainties that could affect the Company's future operating
results and financial condition generally include, without
limitation: (i) the risk that we may not have sufficient funds to
operate our business; (ii)our success in attracting new business
and retaining existing clients and projects; (iii) the size,
duration and timing of clinical trials we are currently managing
may change unexpectedly; (iv) the termination, delay or
cancellation of clinical trials we are currently managing could
cause revenues and cash-on-hand to decline unexpectedly; (v) the
timing difference between our receipt of contract milestone or
scheduled payments and our incurring costs to manage these trials;
(vi) outsourcing trends in the pharmaceutical, biotechnology and
medical device industries; (vii) the ability to maintain profit
margins in a competitive marketplace; (viii) our ability to attract
and retain qualified personnel; (ix) the sensitivity of our
business to general economic conditions; (x) other economic,
competitive, governmental and technological factors affecting our
operations, markets, products, services and prices; (xi) announced
awards received from existing and potential customers are not
definitive until fully negotiated contracts are executed by the
parties; (xii) our backlog may not be indicative of future results
and may not generate the revenues expected; (xiii) our ability to
successfully integrate the business of Remedium Oy, which we
acquired on November 1, 2006; (xiv) the performance of the combined
businesses to operate successfully and generate growth; and (xv)
uncertainties regarding the availability of additional capital and
continued listing of our common stock on Nasdaq. You should not
place undue reliance on any forward-looking statement. We undertake
no obligation to publicly release the result of any revision of
these forward-looking statements to reflect events or circumstances
after the date they are made or to reflect the occurrence of
unanticipated events. Please refer to the section entitled "Risk
Factors" in the Form 10-K for a more complete discussion of factors
which could cause our actual results and financial position to
change. You should not place any undue reliance on these
forward-looking statements which speak only as of the date of this
press release. Additional information concerning factors that might
affect our business or stock price which could cause actual results
to materially differ from those in forward-looking statements is
contained in Encorium Group's SEC filings, including its Annual
Report on Form 10-K for the year ended December 31, 2008 and other
periodic reports under the Securities Exchange Act of 1934, as
amended, copies of which are available upon request from Encorium
Group's investor relations department. DATASOURCE: Encorium Group,
Inc. CONTACT: Philip L. Calamia, Chief Financial Officer, Encorium
Group, Inc., +1-610-975-9533; Alison Ziegler, Cameron Associates,
+1-212-554-5469, Web Site: http://www.encorium.com/
Copyright